Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Heart Failure × Trastuzumab × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 556 Neoplasm Metastasis 33 HER2-positive Breast Cancer 29 Breast Neoplasms, Male 27 Neoplasms 16 Brain Neoplasms 16 Inflammatory Breast Neoplasms 15 Stomach Neoplasms 13 Carcinoma, Non-Small-Cell Lung 12 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 7 Ovarian Neoplasms 7 Endometrial Neoplasms 7 Colorectal Neoplasms 7 Esophageal Neoplasms 6 Cardiotoxicity 6 Pathologic Complete Response 5 Breast Diseases 5 Squamous Cell Carcinoma of Head and Neck 4 Sarcoma 4 Prostatic Neoplasms 4 Lung Neoplasms 4 HER2-positive Early Breast Cancer 4 Carcinoma, Ductal, Breast 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 HER2-positive Metastatic Breast Cancer 3 HER2 Positive Breast Cancer 3 Carcinoma, Ovarian Epithelial 3 Anatomic Stage I Breast Cancer AJCC v8 3

Interventions

Carvedilol 2 sacubitril and valsartan sodium hydrate drug combination 1 pertuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 candesartan 1 Trastuzumab 1 Specimen Handling 1 Secondary Prevention 1 Perindopril 1 Ogivri 1 Metoprolol 1 Exercise 1 Electronic Health Records 1 Echocardiography 1 Carnitine 1 Bisoprolol 1 Adrenergic beta-Antagonists 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04680442 2025-04-06

SCHOLAR-2

Population Health Research Institute

Phase 2 Recruiting

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon ⚡